资源有限地区HIV相关神经认知障碍的多样本评估
基于ACTG 5199国际神经研究,应用国际神经认知常模研究数据评估860名HIV阳性成人的神经认知障碍程度。基线时55%无损伤,轻度25%、中度17%、重度3%;启动ART后每24周损伤比值降低12%(95%CI 9%-14%,P<.0001),轻中度损伤随时间改善。
要点
- 基线近半数HIV感染者存在神经认知损伤,以轻中度为主。
- 启动ART后每24周损伤比值下降12%(95%CI 9%-14%)。
- 轻中度损伤改善后轻度损伤稳定在约18%至168周。
核心结论
- 基于本地常模,近半数HIV阳性者在ART前存在神经认知损伤,启动ART后总体显著降低。
研究设计与样本
- A5199 INS为随机临床试验(ACTG 5175;PEARLS)中的神经认知评估,纳入860名HIV阳性成人。
- ACTG 5271 INNS从10个自愿咨询检测点收集2400名高危HIV阴性者的常模数据用于损伤评级。
主要发现
- 860名HIV阳性成人中,基线55%无神经认知损伤。
- 基线时轻度神经认知损伤占25%,中度占17%,重度占3%。
- 启动ART后,每治疗24周损伤估计比值降低12%(95%CI 9%-14%,P<.0001)。
- 轻度损伤略有下降后,至第168周稳定在约18%。
临床怎么用
- 在资源有限地区应关注HIV感染者启动ART前的神经认知筛查。
- 启动ART后神经认知损伤可随时间显著改善,支持早期治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Neurocognitive impairment remains a common complication of human immunodeficiency virus (HIV) despite effective antiretroviral therapy (ART). We previously reported improved neurocognitive functioning with ART initiation in 7 resource-limited countries for HIV+ participants from the AIDS Clinical Trials Group (ACTG) 5199 International Neurological Study (INS). Here, we apply normative data from the International Neurocognitive Normative Study (INNS) to INS to provide previously unknown rates of neurocognitive impairment. METHODS: The A5199 INS assessed neurocognitive and neurological performance within a randomized clinical trial with 3 arms containing World Health Organization first-line recommended ART regimens (ACTG 5175; PEARLS). The ACTG 5271 INNS collected normative comparison data on 2400 high-risk HIV-negative participants from 10 voluntary counseling and testing sites aligned with INS. Normative comparison data were used to create impairment ratings for HIV+ participants in INS; associations were estimated using generalized estimating equations. RESULTS: Among 860 HIV+ adults enrolled in ACTG 5199, 55% had no neurocognitive impairment at baseline. Mild neurocognitive impairment was found in 25%, moderate in 17%, and severe in 3% of participants. With the initiation of ART, the estimated odds of impairment were reduced 12% (95% confidence interval, 9%, 14%) for every 24 weeks (P < .0001) on ART. Mild impairment dropped slightly and then remained at about 18% out to week 168. CONCLUSIONS: Almost half of HIV+ participants had neurocognitive impairment at baseline before ART, based on local norms. With ART initiation, there were significant overall reductions in neurocognitive impairment over time, especially in those with moderate and severe impairments. CLINICAL TRIALS REGISTRATION: NCT00096824.
引用
- Robertson KR, Jiang H, Kumwenda J, et al. Human Immunodeficiency Virus-associated Neurocognitive Impairment in Diverse Resource-limited Settings. Clin Infect Dis. 2019. PMID: 30219843. doi:10.1093/cid/ciy767
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。